Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-small Cell Lung Cancer Stage IV: early-phase trial registry
3 of 5 indexed Non-small Cell Lung Cancer Stage IV trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Non-small Cell Lung Cancer Stage IV: 5 US clinical trials tracked, 3 recruiting.
Non-small Cell Lung Cancer Stage IV is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Golden Biotechnology Corporation, running 1 of these trials.
Enrollment posture brief
Registry condition non-small-cell-lung-cancer-stage-iv
OPEN 3 | RECR 60% | LATE 0 | EARLY 5 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
Non-small Cell Lung Cancer Stage IV lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-small Cell Lung Cancer Stage IV on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-small Cell Lung Cancer Stage IV is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Non-small Cell Lung Cancer Stage IV research.
Golden Biotechnology Corporation accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Non-small Cell Lung Cancer Stage IV trials plan to enrol fewer than 100 people.
Median target enrolment is 85 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Non-small Cell Lung Cancer Stage IV research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Genelux Corporation
NCT06463665
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
Case Comprehensive Cancer Center
NCT07104630
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
University of California, Davis
NCT07250477
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer
Eli Lilly and Company
NCT02450539
Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC
Golden Biotechnology Corporation
NCT02047344
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-small Cell Lung Cancer Stage IV records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-small Cell Lung Cancer Stage IV trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-small Cell Lung Cancer Stage IV page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Non-small Cell Lung Cancer Stage IV trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Golden Biotechnology Corporation sponsors the most Non-small Cell Lung Cancer Stage IV trials on record, review their full trial history before evaluating a specific study. See Golden Biotechnology Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-small Cell Lung Cancer Stage IV condition card totals 5 registered trials; most-linked intervention Docetaxel; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.